A B S T R A C T The aim of this study was to determine the ability of disodium dichloromethylene diphosphonate (Cl2MDP) to reduce the hypercalcemia secondary to skeletal metastases and induced by stimulation of bone resorption by malignant cells. Five patients with hypercalcemia due to bone metastases of breast or renal cancer were treated orally for 4 wk with 3,200 mg of C12MDP and 4 wk with a placebo in a double blind, crossover study. During the C12MDP period of administration four patients experienced a rapid and significant decrease in serum calcium and urinary calcium excretion together with an increase in alkaline phosphatase. In the remaining patient who developed a sudden paraplegia at the onset ofthe therapy followed by a marked increase in serum calcium levels and urinary calcium excretion, C12MDP was able to reverse this worsening of hypercalcemia or to reduce serum and urinary calcium to normal values. For all patients, urinary hydroxyproline excretion was unchanged during the C12MDP period when compared with the prestudy or placebo periods. From these results, and because ofthe rapid relapse ofhypercalcemia during the placebo period or after withdrawal of the treatment, we can conclude that C12MDP is capable of reducing excessive mobilization of calcium resulting from bone metastases.
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INTRODUCTION
In vitro studies using mouse calvaria have demonstrated that disodium dichloromethylene diphosphonate (Cl2MDP)1 inhibits both parathyroid hormonestimulated and unstimulated bone resorption (1, 2) . Although C12MDP is the most potent inhibitor of bone resorption known, it depresses bone formation less Received for publication 4 February 1980.
1 Abbreviations used in this paper: AP, alkaline phosphatase; C12MDP, disodium dichloromethylene diphosphonate; iPTH, immunoreactive serum parathyroid hormone; OHP, hydroxyproline.
than disodium ethane-l-hydroxy-1, 1 diphosphonate or 3-amino-1-hydroxy-propilidene-1, 1 diphosphonate as demonstrated by both in vitro and in vivo rat studies. C12MDP does not inhibit osteoid mineralization (3, 4) . A recent study on Paget's disease of bone (5), suggests that C12MDP may be a potentially effective treatment for bone diseases characterized by an increased osteoclastic activity, because it induces a decrease in bone resorption without impairing bone mineralization. Osteolytic bone lesions from metastatic origin are mostly the result of the stimulation of bone resorption by malignant cells (6, 7) . Therefore, we carried out a pilot study on the effects of C12MDP on the mobilization of calcium from bone in metastatic disease.
METHODS
The study was a double blind, placebo-controlled, crossover designed trial. It was approved by the local ethics committee.
Patients. Five patients vere selected as having clinical, radiological, and bone scan evidence of skeletal metastases a hypercalcemia >2.75 mmol/liter and <3.75 mmol/liter, and a prognosis for survival of >2 mo. Sex and age ofthe patients and sites of the metastases are summarized in Figs. 1 and 2 . Treatment with mithramycin, calcitonin, phosphorus, indomethacin, or corticosteroids at a dose>15 mg/d were excluded during the week preceding the initiation of C12MDP. In addition, patients demonstrating an increase in serum calcium>0.4 mmol/ liter above the initial value were excluded from the double blind study and treated with C12MDP in an open protocol. During the study patients received chemotherapy and eventually cobalt therapy to the nmost painful lesions. The patients received 3,200 mg C12MDP/d for 4 wk divided into four equal oral doses, and a lactose-containing placebo for 4 wk given in the same manner. All patients were randomly assigned to begin the study with either C12MDP or placebo.
Clinical status was assessed and blood and urine assays performed twice a week. Blood was drawn for calcium (Ca), phosphorus (P), and alkaline phosphatase (AP). Immunoreactive serum parathyroid hormone levels (iPTH) were measured at the onset of the study and again at the end of the 4th and 8th wk. 24-h urine collections were made to measure urinary Ca and hydroxyproline (OHP) during the prestudy and C12MDP periods (Tables I  and II) we found a significant decrease in serum Ca during C12MDP administration in all but one patient (3, with paraplegia). For two patients (1 and 4) receiving placebo after C12MDP, serum Ca values during the placebo period remained lower than the prestudy values. The changes in urine Ca were similar to that in serum Ca (Figs. 1 and 2 ) and the mean values of urine Ca were significantly lower during the C12MDP period than during the prestudy period for all patients. In two (1 and 4) this effect was maintained during the placebo period (Tables I and II) . On the contrary, serum P did not change during the three periods.
Except in patient 1, who had only one metastatic localization, all patients had elevated pretreatment urine OHP consistent with increased bone resorption. During treatment with C12MDP this excretion was not significantly changed (Table I) .
In addition, we noted a progressive increase in serum AP during C12MDP therapy (Table III) (13) with 3-amino-l-hydroxypropilidene-1,1 diphosphonate for the treatment of hypercaleemia from bone metastases but in this study the concurrent effects of chemotherapy were not determined and by Siris et al. (14) with C12MDP for the treatment of skeletal mobilization of Ca in multiple myeloma. Siris et al. (14) nevertheless found a reduction in OHP excretion but this decrease was much smaller than that in Ca excretion and the duration of C12MDP therapy was longer in this study (8 wk) .
From these results and those obtained in the treatment of Paget's disease (5) we can conclude that C12MDP given orally is effective in reducing osteolytic bone destruction due to increased resorption. This reduction in osteoclastic activity is possibly accompanied by a transitory increase in bone formation as reflected by the increased AP. In the management of hypercalcemia of malignancy it remains necessary to better define the effective doses and eventually their adjustment according to the magnitude of hypercalcemia. The duration oftreatment and the best route of administration, the drug being potentially more effective when used intravenously, must be determined. However, C12M DP appears as an effective drug for the treatment of disorders associated with excessive bone resorption and probably for the preventive extension of osteolytic metastases.
